Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P13 versus Remicade in active Crohn's disease
NL-OMON41931Phase 3Active, not recruiting
- Sponsor
- Celltrion
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of infliximab in Crohn's disease (2 arms), sponsored by Celltrion. Primary endpoint: CDAI-70 response at Week 6. Started Jun 2015; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON41931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41931.